Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group.
The International COX-2 Study Group, a panel of independent physicians and scientists, convened January 28-30, 2005, in Washington, DC, to discuss the issues concerning the cardiovascular (CV) profile of coxibs. The purpose of the meeting was to review potential mechanisms by which inhibition of COX-2 by selective and nonselective NSAID could increase risk of CV events, to evaluate the similarities and differences between drugs based on mechanism and pharmacology, and to propose potential trial methodology to more definitively answer questions regarding cardiovascular risk.
Crofford
Leslie J
LJ
Center for the Advancement of Women's Health, University of Kentucky, Lexington, Kentucky, USA.
Breyer
Matthew D
MD
Strand
C Vibeke
CV
Rushitzka
Frank
F
Brune
Kay
K
Farkouh
Michael E
ME
Simon
Lee S
LS
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D006801:Humans; D007391:International Cooperation; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D012219:Rheumatology / Q000379:methods
D052246:Cyclooxygenase 2 Inhibitors; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human